Corporate Actions
Material events companies report to the SEC on Form 8-K: mergers, dividends, buybacks, splits, management changes, bankruptcies and more. Enter a ticker for one company's history, or browse the latest across the market.
Transcode Therapeutics (RNAZ)
1 8-K filing| Filed | Action | What the filing says | SEC |
|---|---|---|---|
| Feb 23, 2026 |
Reg FD Disclosure
Item 7.01Item 9.01
|
Regulation FD Disclosure. On February 23, 2026, TransCode Therapeutics, Inc. (“TransCode”) issued a press release announcing the publication of a manuscript titled Template-Directed RIG-I Agonist Assembly for…Regulation FD Disclosure. On February 23, 2026, TransCode Therapeutics, Inc. (“TransCode”) issued a press release announcing the publication of a manuscript titled Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy in the journal Molecular Imaging and Biology. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing. I |
Filing |
Each 8-K is classified by its most significant item; hover an item number for its title. Classification and excerpts are read automatically and can be wrong; the filing on SEC.gov is the authority. For research, not investment advice.